☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Cervical Cancer
Disease of the Month: Cervical Cancer
January 12, 2023
Agenus Reports the Withdrawal of BLA for Balstilimab to Treat Cervical Cancer
October 25, 2021
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Second Indication in Cervical Cancer
October 14, 2021
Seagen and Genmab's Tivdak (tisotumab vedotin-tftv) Receive the US FDA's Accelerated Approval for the Treatment of Recurrent or Me...
September 22, 2021
Merck Reports Results of Keytruda (pembrolizumab) in P-III KEYNOTE-826 Trial as 1L Treatment for Cervical Cancer
September 20, 2021
Regeneron and Sanofi Present Positive Results of Libtayo (cemiplimab) from P-III Trial for Cervical Cancer at ESMO2021
May 13, 2021
Load more...
Back to Home